Biocept Stock Forecast, Price & News

+0.06 (+1.54 %)
(As of 09/21/2021 12:56 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume5,018 shs
Average Volume693,323 shs
Market Capitalization$58.30 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

Biocept logo

About Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.


Short Interest in Biocept, Inc. (NASDAQ:BIOC) Expands By 29.7%
Short Interest in Biocept, Inc. (NASDAQ:BIOC) Expands By 29.7%
September 20, 2021 |
22 Stocks Moving in Fridays Pre-Market Session - Markets Insider
22 Stocks Moving in Friday's Pre-Market Session - Markets Insider
August 20, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.58 out of 5 stars

Medical Sector

994th out of 1,352 stocks

Medical Laboratories Industry

21st out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Biocept (NASDAQ:BIOC) Frequently Asked Questions

Is Biocept a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept
or view top-rated stocks.

What stocks does MarketBeat like better than Biocept?

Wall Street analysts have given Biocept a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biocept wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Biocept?

Biocept saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 969,600 shares, an increase of 29.7% from the August 15th total of 747,600 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is presently 0.8 days.
View Biocept's Short Interest

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Biocept

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) issued its quarterly earnings results on Sunday, August, 15th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. The medical research company had revenue of $12.05 million for the quarter. Biocept had a negative net margin of 4.02% and a negative trailing twelve-month return on equity of 8.71%.
View Biocept's earnings history

How has Biocept's stock been impacted by COVID-19 (Coronavirus)?

Biocept's stock was trading at $3.7690 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOC shares have increased by 3.2% and is now trading at $3.89.
View which stocks have been most impacted by COVID-19

When did Biocept's stock split? How did Biocept's stock split work?

Shares of Biocept reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for BIOC?

1 brokers have issued 12-month price targets for Biocept's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Biocept's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 414.1% from the stock's current price.
View analysts' price targets for Biocept
or view top-rated stocks among Wall Street analysts.

Who are Biocept's key executives?

Biocept's management team includes the following people:
  • Michael W. Nall, President, Chief Executive Officer & Director
  • Timothy C. Kennedy, CFO, Senior VP-Operations & Secretary
  • Lyle J. Arnold, Chief Scientific Officer & Senior Vice President
  • Michael C. Dugan, Chief Medical Officer & Medical Director
  • Michael W. Brown, General Counsel, Compliance & Privacy Officer

What is Michael Nall's approval rating as Biocept's CEO?

1 employees have rated Biocept CEO Michael Nall on Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Biocept's key competitors?

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.91%), Morgan Stanley (1.33%), Morgan Stanley (1.21%), GSA Capital Partners LLP (1.13%), Geode Capital Management LLC (1.01%) and Citadel Advisors LLC (0.00%).
View institutional ownership trends for Biocept

Which institutional investors are selling Biocept stock?

BIOC stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Vanguard Group Inc., and Simplex Trading LLC.
View insider buying and selling activity for Biocept
or view top insider-selling stocks.

Which institutional investors are buying Biocept stock?

BIOC stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, GSA Capital Partners LLP, State Street Corp, Virtu Financial LLC, Susquehanna International Group LLP, Geode Capital Management LLC, and Sabby Management LLC.
View insider buying and selling activity for Biocept
or or view top insider-buying stocks.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $3.89.

How much money does Biocept make?

Biocept has a market capitalization of $57.27 million and generates $27.46 million in revenue each year.

How many employees does Biocept have?

Biocept employs 107 workers across the globe.

What is Biocept's official website?

The official website for Biocept is

Where are Biocept's headquarters?

Biocept is headquartered at 5810 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at (858) 320-8200 or via email at [email protected].

This page was last updated on 9/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.